New test could prevent unneeded prostate cancer treatment

A new test from Genomic Health, the Oncotype DX Prostate Cancer Test, could reduce the number of men who undergo treatment for low-risk prostate cancer that would be better left untreated. The test rates the aggressiveness of a prostate biopsy based on an analysis of 17 genes and is more accurate than currently available tests, the developers say.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY